GLP-1 Weight-Loss Drugs and Heart Risk

How Do GLP-1 Drugs Affect Heart Attack and Stroke Risk?

GLP-1 receptor agonists, including semaglutide and related medicines, were first developed for type 2 diabetes and later became major obesity treatments because they reduce appetite, slow gastric emptying, and improve glucose regulation. Cardiovascular researchers are now focused on a broader question: whether these drugs also reduce hard outcomes such as heart attack, stroke, cardiovascular death, and heart failure hospitalization.

A 2026 systematic review in Cardiovascular Diabetology - Endocrinology Reports analyzed 11 randomized, placebo-controlled cardiovascular outcome trials involving 91,490 participants. The review found that GLP-1 receptor agonist therapy was associated with fewer major adverse cardiovascular events, with reductions also reported across several secondary outcomes including cardiovascular mortality, all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure.

Why Was the SELECT Trial Important for People Without Diabetes?

The SELECT trial, published in The New England Journal of Medicine in 2023, was a turning point because it studied adults with established cardiovascular disease and overweight or obesity but without diabetes. Participants received once-weekly semaglutide 2.4 mg or placebo, alongside usual cardiovascular care.

The trial reported a 20% relative reduction in the composite endpoint of cardiovascular death, nonfatal heart attack, or nonfatal stroke. That result helped shift the clinical conversation from weight loss alone to cardiometabolic risk reduction, and it supported the FDA's 2024 approval of Wegovy for reducing cardiovascular death, heart attack, and stroke risk in adults with established cardiovascular disease and overweight or obesity.

Who Might Benefit Most From GLP-1 Heart Protection?

The strongest data are not for low-risk people seeking cosmetic weight loss. They apply to patients with a high baseline risk of cardiovascular events, including many adults with prior heart attack, stroke, peripheral artery disease, type 2 diabetes, obesity, hypertension, or chronic kidney disease. For these patients, even a modest relative risk reduction can translate into meaningful public health benefit.

Clinicians still need to individualize treatment. GLP-1 medicines can cause gastrointestinal adverse effects, are not appropriate for everyone, and may be difficult to access because of cost or supply constraints. They should complement, not replace, proven prevention strategies such as statins when indicated, blood pressure control, smoking cessation, physical activity, sleep, and nutrition.